PTEN is a well-described predisposition gene for Cowden syndrome (CS), a familial cancer syndrome characterized by a high risk of breast and other cancers. KLLN, which shares a bidirectional promoter with PTEN, causes cell cycle arrest and apoptosis. We previously identified germline hypermethylation of the KLLN promoter in 37% of PTEN mutation-negative CS/CS-like (CSL) patients. Patients with germline KLLN hypermethylation have an increased prevalence of breast and renal cancers when compared with PTEN mutation carriers. We have consequently sought to identify and characterize germline KLLN variants/mutations in CS/CSL and in apparently sporadic breast cancer patients. KLLN variants in CS/CSL patients are rare (1 of 136, 0.007%). Interestingly, among 438 breast cancer patients, 13 (3%) have germline KLLN variants when compared with none in 128 controls (P 5 0.049). Patients with KLLN variants have a family history of breast cancer when compared with those without (P 5 0.02). We demonstrate that germline KLLN variants dysregulate the cell cycle at G2. Of 24 breast carcinomas analyzed, 3 (13%) have somatic KLLN hemizygous deletions, with somatic loss of the wild-type allele in a patient with germline KLLN p.Leu119Leu. Of 452 breast carcinomas in The Cancer Genome Atlas project, 93 (21%) have KLLN hemizygous or homozygous deletions. This is the first study to associate germline KLLN variants with sporadic breast cancer and to recognize somatic KLLN deletions in breast carcinomas. Our observations suggest that KLLN may be a low penetrance susceptibility factor for apparently sporadic breast cancer.
INTRODUCTION
Breast cancer is the most common form of cancer and the leading cause of cancer-related mortality in women worldwide (1) . Known risk factors that influence the development of breast cancer are age of menarche and menopause, alcohol consumption, obesity, breast feeding, nulliparity and others (2) . Notably, women with a first-degree relative with breast cancer have a 2-fold greater risk of developing breast cancer that is indicative of a genetic susceptibility (3) . At least 12 different Mendelian predisposition genes have been associated with an increased risk of breast cancer, including BRCA1 and BRCA2, responsible for hereditary breast and ovarian cancer syndrome. Other high penetrance breast cancer-predisposition genes include PTEN and TP53, genes associated with Cowden syndrome (CS) and Li -Fraumeni syndrome, respectively (3 -5) . A number of low and moderate penetrance genes contributing to breast cancer risk have been identified through genomewide association studies or candidate gene studies. In general, the Mendelian cancer predisposition alleles are inherited in an autosomal dominant manner, whereby patients carry the heterozygous mutated allele in their germline, and in the tumor, there is often a loss of the wild-type allele through deletion, methylation or another mechanism (3) . Although there are now at least 12 high penetrance Mendelian breast cancer susceptibility genes, these genes only account for up to 25% of breast cancer cases considered to be familial (3, 6, 7) . It remains a challenge to sort through whether the apparently sporadic presentation of breast cancer is truly sporadic or has a heritable factor. The identification of additional predisposition genes will lead to more effective cancer risk assessment, genetic counseling and gene-informed management.
Patients with the autosomal dominant CS, characterized by multiple hamartomas and a risk of various solid tumors, have up to an 85% lifetime risk of developing breast cancer (8) . Although PTEN is believed to be the major gene causative for CS, our recent study of 3042 probands with classic CS/CS-like (CSL) phenotypes revealed that only 25% of community-accrued CS and 5% of CSL probands have germline pathogenic PTEN mutations (9) . Initial linkage studies, performed when the hunt for the CS gene was underway, pointed to the10q23 chromosomal region alone, without indication of genetic heterogeneity (10) . KLLN (MIM 612105) was recently identified at 10q23.31 and shares a bidirectional promoter with PTEN (11). We found germline hypermethylation of the KLLN gene promoter in 37% of PTEN mutationnegative CS and CSL patients (8, 12) . Hypermethylation of the promoter causes a 250-fold decrease in KLLN expression without affecting PTEN expression (9) . KLLN, like PTEN, is regulated by p53 and mediates cell cycle arrest and apoptosis and consequently is a potential tumor suppressor gene (11) . Furthermore, patients with KLLN promoter hypermethylation have a greater than 2-fold increased prevalence of breast and renal cancer when compared with those with PTEN mutations (12) . We subsequently found germline KLLN promoter hypermethylation in 56% of patients with sporadic renal cancer, and somatic KLLN promoter hypermethylation is seen in renal cell carcinoma tumors with increasing methylation with increasing stage (13) .
We, therefore, sought to address the hypothesis that germline intragenic mutations of the putative tumor suppressor gene KLLN could be found in PTEN mutation-negative CS/ CSL patients and might also be identified in patients with apparently sporadic breast cancers, as a forme fruste of CS/CSL.
RESULTS
Germline KLLN mutation analysis in CS/CSL patients and in breast cancer patients
We scanned 136 PTEN mutation-negative CS/CSL patients for KLLN variants and found only 1 variant c.49G . A, p.Val17Ile 0.007% (Supplementary Material, Table S1 ). This patient had ductal breast carcinoma, but only had a Cleveland Clinic score of 6 via the PTEN Cleveland Clinic Risk Calculator, a tool developed to predict the likelihood of a PTEN mutation by examining the phenotypes of CS/CSL patients with pathogenic PTEN mutations, indicating ,1% pretest probability for germline PTEN mutation (9) . Given the very low frequency of KLLN variants in our CS/CSL series and noting the patient's breast cancer diagnosis, we then focused on analyzing germline KLLN in an unselected nested series of 393 prospectively accrued unrelated patients with invasive breast cancer. The characteristics of these breast cancer patients are described in Supplementary Material, Table S2 .
Of the 393 patients in the CCF-Breast study, 10 (2.5%) were found to carry germline variants in the KLLN gene (Table 1) . Among the 10 patients with variants, 2 were African-American (AA) and 8 were Caucasian, a greater proportion of variants in AA patients than expected in the CCF-Breast study (P ¼ 0.03). We consequently screened an independent series of 47 AA patients (AA-Breast cohort) with invasive breast cancers and found 3 (6.4%) to have KLLN variants. Despite only two males screened in the AA-Breast cohort, one of the variants identified in KLLN was seen in a male patient (P ¼ 0.12). Overall, 13 of 438 (3%) patients in the CCF-Breast and AA-Breast cohorts have exonic KLLN variants ( (Table 2) .
There is a broad spectrum of germline KLLN variants observed in the patients: two patients had frameshift mutations, one patient had an indel, five patients had missense mutations and five patients had synonymous variants (Table 2) . When multiple missense mutations are observed in any single individual, these mutations occur in cis (data not shown). Of the missense mutations, three of the four are classified by both PolyPhen and SIFT variation prediction tools as probably affecting protein function (Supplementary Material, Table S3 ). The variant p.Asn131Ser is classified as benign, but interestingly, this variant always occurs in combination with another missense mutation.
To determine if there are larger copy number variations (CNVs) of the KLLN gene in patients with breast cancer, we performed a pilot study using quantitative PCR (qPCR) CNV primer probe sets for the KLLN exon in 74 patients in the CCF-Breast study. Of the 74, 4 (5.4%) patients were found to have germline duplications, but 2 of 38 (5.2%) controls also have duplications, likely representing the known CNV in this region reported by the Database of Genome Variants (Variation_85423). Because we did not see a significant difference between cases and controls, we did not expand the CNV analysis to the entire cohort.
Clinicopathologic characteristics of patients with germline KLLN variants
No differences were seen in the ages of patients with KLLN variants [mean 57 years, 95% confidence interval (CI) Tables S4 and S5 ). There was no significant difference in the clinicopathologic or somatic molecular profile, including the estrogen receptor (ER), progesterone receptor (PR) and Her2Neu status, between those with and without a germline KLLN mutation. The majority of patients in both groups were ER and PR positive and Her2Neu negative (Supplementary Material, Table S4 ). We then analyzed family breast cancer histories between these two groups. One patient with a KLLN variant was adopted and consequently not included in the analysis. The remaining patients with germline KLLN variants have multiple family members who have a diagnosis of breast cancer when compared with those without KLLN variants (P ¼ 0.02, Table 3 ).
Functional consequences of KLLN variants
To determine the consequence of KLLN variants on KLLN transcription, qPCR of mRNA from patient blood lymphocytes was performed. KLLN mRNA is decreased in the patients with frameshift mutations (P ¼ 0.02, Fig. 1A ). Interestingly, there is also a trend toward decreased KLLN transcript in patients with synonymous variants (P ¼ 0.05, Fig. 1A ).
To further evaluate the function of specific germline variants observed in breast cancer patients, lymphoblast cell lines representing different patient germline KLLN variants and wild-type controls were analyzed for alterations in cell cycle regulation. We observed a decrease in the percentage of cells in the G2 phase of the cell cycle for patient lymphoblasts with KLLN variants when compared with wild-type controls (Fig. 1B ) without significant differences in the other phases of the cell cycle. After synchronizing cells to progress through the S/G2 boundary, protein levels of CHK1, a mediator of cell cycle arrest, were significantly decreased in patient lymphoblasts with KLLN variants when compared with controls (Fig. 1C) , which was replicated with increased acquisition intensity and antibody concentration (Supplementary Material, Fig. S1 ). A decrease in CHK1 protein in patients with germline variants may account for the G2 deregulation. No differences in PTEN protein levels were observed between lymphoblasts with KLLN variants when compared with controls (Fig. 1D) .
We next investigated how synonymous variants could be affecting KLLN. One mechanism in which synonymous variants can decrease translation is by changing the wild-type codon to a rare codon (14) . Here, we determined that for the synonymous variants, p.Leu119Leu, p.Leu129Leu and p.Arg54Arg, the variants result in a less frequently used codon, 19.6 -13.2%, 12.9-7.7% and 11.4 -6.2%, respectively (15) . To investigate this in vitro, we treated cells with bortezomib, a proteosome inhibitor, and assayed for how much protein had accumulated. There was a decrease in KLLN protein in lymphoblasts with these synonymous variants when compared with controls ( Fig. 1E) Knockdown of KLLN expression with siRNA in the breast cancer cell line MCF7 resulted in comparable results to lymphoblasts with KLLN variants. KLLN knockdown is accompanied by a concurrent decrease in CHK1 expression ( Fig. 2A and B ). There is no significant change in other key mediators of cell cycle regulation and apoptosis. Neither 
F, female; M, male; AA, African-American; C, Caucasian; MAF, minor allele frequency. BAX, an indicator of apoptosis, nor CDKN1A, an important player in G1 arrest, is affected by knockdown of KLLN ( Fig. 2C and D) . Furthermore, after KLLN with a 3xFLAG tag was expressed in MCF7 cells, KLLN was found to bind to the CHK1 promoter between 2184 and 2384 suggesting that KLLN is acting as a regulator for CHK1 transcription ( 
Analysis of tumor samples for somatic KLLN deletions/loss of heterozygosity
To obtain evidence supporting a role of KLLN as a tumor suppressor broadly acting in breast cancers, we examined breast cancer tumor samples for somatic KLLN CNV. Tumor and adjacent normal tissue from 7 patients with germline KLLN variants and 16 patients without germline KLLN variants were microdissected and analyzed. Loss of one of the KLLN alleles was observed in 3 out of the 23 tumors (13%), but not in any normal tissue (Fig. 3A) . In one case, the heterozygous germline variant, c.357 C.T p.Leu119Leu, was found by Sanger sequencing to be heterozygous in the normal tissue and hemizygous in the tumor (Fig. 3B) Fig. S4B ).
There is an accompanying decrease in KLLN transcript expression in tumors with KLLN monoallelic deletions and a greater decrease with homozygous deletions (Supplementary Material, Fig. S5 ). No differences were seen in the ages of patients with tumor-associated somatic KLLN deletions (mean 59 years, 95% CI 56-62) when compared with those without (mean 57 years, 95% CI 56-59). Notably, tumors with somatic KLLN deletions are more likely to be both ER-and PR-negative (P ¼ 0.014 and P ¼ 0.005, Table 4 ). Because tumors with KLLN deletions were likely to be hormone negative, we wanted to examine if they were also likely to be of a basal subtype by their expression profile. Tumors with KLLN deletions were found to be significantly associated with a basal subtype (P ¼ 0.002, Table 4 ).
To better understand KLLN expression in breast tumors versus normal tissue, TCGA RNA-seq data for KLLN expression were available and analyzed in 79 total breast carcinomas and 79 matched normal breast tissues. A significant decrease in KLLN expression is seen in 70 breast tumors that do not harbor a KLLN deletion, when compared with matched normal tissue (Fig. 3C) . There is also a significant decrease in KLLN expression in nine breast tumors with a KLLN deletion when compared with matched normal tissue (Fig. 3D) .
DISCUSSION
In contrast to finding germline KLLN promoter hypermethylation in 37% of patients with CS/CSL (12), we demonstrate that only 0.007% of CS/CSL patients have germline KLLN variants. These observations suggest that epigenetic regulation, but not structural alterations, of KLLN is the dominant mechanism for predisposition to CS/CSL. In contrast, 3% of individuals with apparently sporadic breast cancer, a CS/CSL component cancer, carry germline KLLN variants when compared with none in in-house population controls and a combined minor allele frequency of 0.014 in the 1000 Genomes Project, thus, suggesting that KLLN may be a lowpenetrance breast cancer susceptibility gene. These observations also lend credence to the belief that rare genomic variants in the general population may turn out to be important low to moderate penetrance predisposition alleles. Although sample sizes of our AA-Breast cohort are small, it is tantalizing to postulate that KLLN variants may be an important mechanism of low-penetrance breast cancer predisposition in the AA population when compared with whites, but this will need to be explored in an larger independent cohort. Often low-penetrance variant-associated diseases do not necessarily possess the high-risk clinical signs such as early age of onset, multifocal disease or familial clustering (6) . Here, we show that breast cancer patients with germline KLLN variants do not have younger ages of breast cancer diagnosis than those without KLLN variants. Similarly, unlike the basal-like (triple negative) predominance of BRCA1/2 breast carcinomas (16,17), we do not see any large differences in specific clinicopathologic features in those with KLLN germline variants when compared with those without. Germline KLLN mutations occur in the setting of simplex cases and familial clusters. It is important to note that we include all family members of the proband reported to have had breast cancer in the family history analysis. We chose this less stringent approach than criteria that only include first-and second-degree relatives; our approach is more likely to pick up a family history exhibiting low penetrance patterns for the phenotype of interest. The family-phenotypic hallmarks of low to moderate penetrance genes are occurrence of apparently sporadic (simplex) cases showing manifestation of the disease and/or familial clustering of the disease in a non-specific pattern and without carrying the clinical 'red flags' of hereditary patterns (e.g. the latter includes clear autosomal dominant segregation, early ages of onset and bilateral disease in paired organs) (3, 6) .
Thus, KLLN appears to be a low to moderate penetrance breast cancer predisposition gene. We analyzed a subset of our cases and controls for CNVs. CNVs have been increasingly recognized as an important source of both genetic diversity and of disease predisposition. Whereas duplications have been previously associated with cancer predisposition by leading to gene hypermethylation, the majority of CNVs are common in the population and 40% have been found to overlap with known reference genes (18) (19) (20) (21) . In our case, we observed a duplication that was previously reported and was at similar frequency in our cases and controls (5.4 and 5.2%, respectively) and so, most likely represents a common polymorphism and not disease causing.
Previously Thompson et al. (22) examined KLLN as a high penetrance breast cancer susceptibility gene by analyzing a group of high-risk Australian and New Zealand breast cancer patients for KLLN mutations. The paper focuses on an individual frameshift mutation that is observed in their control population, this same mutation was not observed in the larger 1000 Genomes Project. Interestingly, they found 5 other KLLN variants in 12 cases that are not seen in their controls. Our observations here are in agreement with this previous report, where indeed, no high penetrance KLLN mutations are found in the CS/CSL cohort of syndromic breast cancer cases. KLLN, such as CHK1 and ATM, is likely to be a lowpenetrance predisposition gene rather than a high penetrance gene.
We further derive in vitro evidence that the germline KLLN variants observed in patients with breast cancer have functional consequences on gene expression and ultimately cell cycle regulation. Whereas germline frameshift mutations leading to decreased KLLN transcript are aligned with existing mechanisms, such as nonsense-mediated decay, it was surprising that germline synonymous KLLN variants also exhibit a decrease in KLLN transcript. These variants may be directly affecting gene transcription or leading to unstable mRNA, which is consistent with the postulated differential codon usage. Certain PTEN and TP53 heterozygous mutations have been found to result in haploinsufficiency and have a significant impact on tumor formation (9, 23) .
Often, synonymous variants have been overlooked and discarded as harmless SNPs. However, recent studies have shown functional consequences of synonymous mutations through decreased transcription, translation and altered protein folding (14, 24, 25) . The decrease in KLLN protein in patientderived lymphoblasts with synonymous variants that result in a rare codon after bortezomib treatment could be a result of decreased KLLN translation in these cell lines. Bortezomib inhibits the degradation of protein, and consequently, if translation is slowed down, then less protein would accumulate after treatment. It is interesting to postulate that codon usage could be the mechanism for decreased KLLN translation with these synonymous variants. One way or another, these synonymous variants also have downstream signaling consequences.
Patient lymphoblasts with KLLN variants have a decrease in the G2 phase of the cell cycle that suggests altered checkpoint control at the G2/M boundary. The decrease in CHK1 expression in lymphoblasts with KLLN variants and after KLLN knockdown represent a plausible mechanism for this altered cell cycle arrest. CHK1 is crucial in responding to DNA damage and stalled replication, leading to arrest at the G2/M checkpoint (26, 27) . CHK1 is a labile protein that is normally expressed during S and G2 phase cells (28) . Given that KLLN binds to the CHK1 promoter and decreased KLLN affects CHK1 mRNA levels, it is possible that KLLN is necessary for the normal oscillating levels of CHK1. Consequently, KLLN may have a role in the DNA damage response pathway, a pathway, where multiple genes have been linked to breast cancer predisposition, e.g. BRCA1/2, ATM and CHK2 (29) . The analyzed KLLN variants were associated with altered cell cycle regulation with a decrease in G2 arrest likely mediated by decreased CHK1. These experiments indicate that the KLLN variants found in breast cancer patients do affect cell cycle regulation and, consequently, may be playing a part in the development of cancer. Additionally, the KLLN overexpression data are consistent with the knockdown and mutant studies, showing that KLLN does lead to a decrease in cellular proliferation possibly through arresting cells at the G2 checkpoint. Although KLLN can directly bind DNA, it is unknown if KLLN binds as a complex with other transcription factors. To further investigate the region on the CHK1 promoter that KLLN binds to, the region between 2184 and 2384 from the CHK1 translation start site was scanned for predicted transcription factor binding sites using both the TFSEARCH and TESS programs (30, 31) . This region of interest is predicted to contain one transcription factor-binding motif, c-ETS, identified by both prediction tools. The Ets-domain transcription factors tend to bind DNA with other transcription factors and are involved in a range of cellular processes that can be dictated by the binding partner (32) . It would be interesting to explore whether KLLN binds with an Ets-domain transcription factor to augment transcriptional activation.
Typically, as in the case for TP53 and PTEN, we expect to see somatic alteration of KLLN in a subset of sporadic tumors. In the case of PTEN, sporadic breast carcinomas show somatic loss of PTEN expression by a variety of genetic and epigenetic mechanisms (33) (34) (35) . To explore somatic relevance of KLLN in breast cancer, we examined KLLN expression between normal breast and breast tumor samples. The data showing decreased KLLN in all tumors lend further genetic-based support that KLLN is a tumor suppressor gene and is decreased in expression in breast tumors by deletion and/or other mechanisms such as methylation. We further examined tumors for somatic loss of the mutant allele. Loss of heterozygosity (LOH) of the p.Leu119Leu variant may represent a second hit to the KLLN gene, suggesting a role of the variant in disease pathogenesis. We did not observe LOH of the wild-type allele in tumors belonging to patients carrying the other germline variants analyzed, but other mechanisms of loss of the wild-type allele, such as epigenetic modifications, could be occurring (3). Combining our samples with the TCGA samples, we found that 20% of breast carcinomas have somatic KLLN deletions. We were able to take advantage of the larger TCGA dataset to determine that tumors with somatic KLLN deletions are more likely to be ER-and PR-negative as well as to be of a basal subtype. These data could form the basis of future studies of survival and therapy response rates for patients with somatic KLLN alterations. Interestingly, clinical trials are testing CHK1 inhibitors as sensitizers to certain classes of chemotherapeutic agents, and in the setting of p53 defects, such inhibitors result in 'mitotic catastrophic' and apoptosis (36, 37) . Tantalizingly, therefore, knowing that germline or somatic KLLN alterations lead to decreased CHK1 would suggest that these cancers would be particularly sensitive to DNA damaging agents or anti-metabolites.
Although the data generated in the TCGA project are remarkable and guide breast cancer classification, there are limitations when focusing on the individual gene level (38) . In the case of KLLN, the exome capture kits used for sequencing in the breast TCGA project did not include the KLLN exon (38) . This means that KLLN is less likely to already have been picked up as an important mediator of breast cancer. This is also the case for previous studies that have used exome capture kits to investigate genes mutated in breast cancer (39, 40) . In contrast, studies looking for CNVs in breast cancer have identified the 10q23.31 region that contains KLLN, as lost (41) (42) (43) . Deletions at 10q23 have previously been previously linked to PTEN, but there have been suggestions based on the pattern of loss that there is another tumor suppressor that lies close to PTEN that we believe to be KLLN (43) (44) (45) .
Whereas structural KLLN alterations were rare in CS/CSL patients, we have obtained evidence of germline KLLN variants specifically in patients with apparently sporadic breast cancer. These variants appear to have functional consequences on G2 checkpoint control. Furthermore, we have established that there are somatic KLLN deletions in breast cancer that support a role of KLLN as a tumor suppressor gene. We believe that it is imperative to explore KLLN to understand the risks of carrying a germline KLLN variant and the biology involved with sporadic KLLN alterations in breast cancer. Table S1 ) or relaxed criteria (criteria minus one) for CSL patients. When necessary, and mandatorily from July 1, 2009, the phenotype was established through pathological and imaging reports. For purposes of this study, we chose a nested cohort of 136 unrelated research participants who were known to be PTEN mutation negative, as a pilot that was powered at P . 0.99 conservatively assuming a mutation frequency of 5%.
MATERIALS AND METHODS

Patients
A separate cohort of 644 unrelated adult female patients with a pathological diagnosis of invasive breast cancer were prospectively accrued from the Cleveland Clinic main campus and community hospital system between 2008 and 2012 and provided informed consent to IRB #CASE2107-CC302 (CCF-Breast study). Patients were recruited to this study regardless of family history of breast or ovarian cancer. In the CCF-Breast study, the average age was 57 years, and patients were mostly Caucasian (92%), reflecting the patient population seen at the Cleveland Clinic (Supplementary Material, Table S2 ). A family history of cancer was provided by each patient, and a chart review was completed to obtain all relevant information about the patient's breast cancer. Of these 644 patients, a random series of the most readily available 393 cases from the Genomic Medicine Biorepository were chosen for KLLN variant screening.
A third cohort, comprising 47 unrelated AA (AA-Breast cohort) patients with invasive breast cancer, was enrolled under IRB8458-PTEN after attending cancer genetics clinics for general banking or specifically for PTEN mutation testing. In this cohort, two (4%) of the patients were male, and the average age was 57 years (Supplementary Material, Table S2 ).
One hundred and twenty-eight population controls, from the region, with no known cancer history were recruited through Cleveland Clinic IRB #06-716. Informed consent was obtained from all participants in this study.
Variant analysis
Germline analysis Genomic DNA isolated from peripheral blood was PCR amplified and Sanger sequenced (ABI3730xl, Carlsbad, CA, USA) for KLLN using primers that cover the entire KLLN exon, including -111 to +29. For patients with multiple variants in KLLN, PCR products were TOPO cloned (Life Technologies, Carlsbad, CA, USA), and individual colonies were sequenced for KLLN.
Somatic tumor analysis
Four micron sections from paraffin-embedded breast cancer tumor blocks were sectioned and stained with hemotoxylin and eosin and read by a single breast pathologist (E.D.K.), who marked tumor and normal tissue for each sample. Tumor and normal tissue were laser capture microdissected using a 10× objective (Leica, Wetzlar, Germany). DNA was extracted using the QIAamp DNA extraction kit (Qiagen, Valencia, CA, USA) after a 2 day proteinase K digestion. CNV was assessed using a TaqMan (Life Technologies) assay to analyze KLLN relative to ACTIN (Life Technologies). qPCR was performed with 10 ng DNA on a Roche LightCycler 480 (Indianapolis, IN, USA). qPCR results were analyzed using the standard DDCT method normalizing to control genomic DNA (Promega, Fitchburg, WI, USA).
When a patient had a germline variant and a deletion in the tumor, the tumor and adjacent normal tissue were Sanger sequenced using the KLLN primers described above. Any tumor with a KLLN deletion was further analyzed for a PTEN deletion using the PTEN Taqman primer probe set for exon 1 along with the ACTIN Taqman primer probe set as a control (Life Technologies).
Germline CNV analysis
For a pilot study of 74 patients in the CCF-Breast study and 38 controls, CNV analysis was also performed on germline DNA for the KLLN gene as described above.
Cell culture and transfection MCF7 cells, which were obtained from ATCC (Manassas, VA, USA) that uses short tandem repeat profiling to verify cell line identity, were maintained in DMEM with 10% fetal bovine serum. For knockdown experiments, the KLLN siRNA smartpool or a control siRNA pool (Darmacon, Lafayette, CO, USA) was transfected into MCF7 cells using Oligofectamine (Life Technologies) in reduced serum media that were replaced with full serum after 4 h. Cells were harvested 48 h later.
For KLLN overexpression studies, KLLN in a pCDNA3 vector (Life Technologies) and vector alone were transfected into MCF7 cells using Lipofectamine LTX (Life Technologies) in reduced serum media that were replaced with full serum after 4 h. At least two independent wells were counted after a 50% dilution with trypan blue (Life Technologies) on a hemocytometer. At the 12 h time point, wells were collected for FACS analysis.
Lymphoblast patient cell lines were maintained in 20% serum Roswell Park Memorial Institute medium as previously published (46) (47) (48) (49) . When stated, cells were synchronized using 2 mM hydroxyurea for 19 h followed by a 4 h release (50) . When stated, cell were treated with the proteosome inhibitor bortezomib (10 mM) or dimethyl sulfoxide alone for 16 h at which time, cells were collected.
Protein collection and western blots
Protein was collected from whole cell lysates using Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA) along with a cocktail of protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Protein was quantified through BCA analysis (Pierce) and subsequently separated on a TGX Any KD gel (Biorad, Hercules, CA, USA). Gels were transferred for 7 min at 2.5 A using the Trans-Blot Turbo system (Biorad) to a nitrocellulose membrane and probed for either CHK1 at 1:500 and 1:100 dilutions (Cell Signaling, Danvers, MA, USA), PTEN 1:1000 dilution (Cascade Biosciences, Colfax, WI, USA), KLLN at 1:100 dilution (Abcam, Cambridge, MA, USA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) at 1:20 000 dilution (Cell Signaling), ANTI-FLAG M2 at 1:2000 dilution (Sigma-Aldrich) or ACTIN at 1:10 000 dilution (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The blots were viewed and quantified using the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE, USA).
Cell cycle analysis
Cells were serum starved for 12 h followed by 48 h of growth with full serum and collected. Cells were collected and washed with cold PBS, fixed in 70% ethanol for at least a half hour and stored at 2208C at least overnight. Cells were stained with propidium iodide for 30 min at 378C and placed on ice for an additional 15 min. FACS was performed by the Cleveland Clinic Flow Cytometry Core.
RNA extraction and qPCR
RNA was either extracted from patient blood or from patientderived cell lines using the RNAeasy Mini kit (Qiagen). RNA was Turbo DNase treated according to protocol (Life Technologies). Reverse PCR was carried out using Superscript III Reverse Transcriptase (Life Technologies). cDNA was quantified using a SYBR Green PCR Master Mix (Life Technologies) with primers designed for each gene. Results were analyzed using the standard DDCT method.
TCGA data analysis
TCGA breast cancer study dataset of 452 tumors was analyzed using the cBio Cancer Genomics Portal (51) . Copy number was assessed using the Genomic Identification of Significant Targets in Cancer algorithm applied to Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) data for the 452 tumors (52) . RNAseq was done using the AgilentG4502A_07 platform (Santa Clara, CA, USA). Normalized RNA-seq by expectation maximization (RSEM) values from RNA-seq data were analyzed for breast tumor-normal comparisons (53) . Clinical data were obtained from the TCGA center Biospecimen Core Resource. Basal subtype classification of TCGA tumors was obtained from the TCGA Network paper (38) . We were unable to examine KLLN for exonic mutations in this dataset because KLLN was not included in the exome capture kits used for the TCGA analysis.
Statistics
Percentage of KLLN variants in patients with breast cancer was compared with controls using a Chi-square test with significance P , 0.05. Age at diagnosis of breast cancer between groups was analyzed using a one-way analysis of variance with significance P , 0.05. Those in the CCF-Breast study had clinical data available for tumor comparisons and are represented in Table 3 and Supplementary Material, Tables S4 and S5. All data in the tables were collected and verified by chart review and represent the first diagnosis of breast cancer, if a patient had a subsequent occurrence. Patient and tumor characteristics were compared between groups using Fisher's two-tailed exact test with Bonferroni's posttest correction for multiple testing with significance set at P , 0.05. A patient with missing or indeterminate information for any given variable was not included in the analysis for the variable. Statistical significance of qPCR and western data was determined using the Student's t-test with significance set at P , 0.05.
Chromatin immunoprecipitation (ChIP)
MCF7 cells were transfected with a pCMV-3Tag-1 vector (Agilent) containing KLLN with a 3xFLAG using Lipofectamine LTX (Life Technologies) according to the protocol in serum-free media with the addition of full serum after 5 h. Forty-eight hours after transfection, the EZ ChIP Kit protocol (Millipore, Billerica, MA, USA) was followed using both an IgG antibody (Millipore) and the ANTI-FLAG M2 antibody (Sigma-Aldrich). Five primers sequentially along the CHK1 promoter from +27 to 21051 were used for qPCR of purified DNA from the ChIP protocol and the input DNA as a control. qPCR data were analyzed using the percent input method. The ChIP assay with FLAG and IgG antibodies was repeated and followed by PCR of the 2184 to 2384 region.
